Research map: MYC rearrangement improves the predictive efficacy of the double-hit model in newly diagnosed multiple myeloma

Back to the article

Papers in this map

  1. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome · Hervé Avet‐Loiseau · 2007 · 915 citations · Cited by this paper
  2. 61eP Radiotherapy combined with PARP inhibition in BRCA-mutated breast cancer: A systematic review of clinical outcomes and toxicity · 2026 · Related
  3. Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013 · Joseph R Mikhael · 2013 · 502 citations · Cited by this paper
  4. Nectin-4 and Trop-2 expression in collecting duct carcinoma: new promising therapeutic targets · 2026 · Related
  5. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders · F. M. Ross · 2012 · 327 citations · Cited by this paper
  6. 149P Adjuvant radiotherapy outcomes for early stage (stage 1c-2) clear cell ovarian carcinoma in Edinburgh cancer centre · 2026 · Related
  7. Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors · Hervé Avet‐Loiseau · 2001 · 290 citations · Cited by this paper
  8. 213P Glandular tissue–based versus anatomical landmark–based CTV delineation in postoperative breast cancer radiotherapy: A dosimetric comparison · 2026 · Related
  9. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma · Luciano J. Costa · 2021 · 270 citations · Cited by this paper
  10. 194eP Ovarian cancer during pregnancy: Maternal and fetal outcomes from a systematic review and meta-analysis · 2026 · Related
  11. Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients · on behalf of the NCRI Haemato-oncology CSG · 2017 · 240 citations · Cited by this paper
  12. 67RO Single-cell and TCR profiling reveals pre-existing cytotoxic CD8 T cell clonal expansion and peripheral–tumor dissociation associated with response to PD-1-based therapy in hepatocellular carcinoma · 2026 · Related
  13. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients · Brian A. Walker · 2014 · 186 citations · Cited by this paper
  14. 219P Clinical profile and treatment outcomes of lymphoma patients: A retrospective cohort study · 2026 · Related
  15. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma · Hervé Avet‐Loiseau · 2025 · 183 citations · Cited by this paper
  16. A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma) · 2026 · Related
  17. Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas · An Na Seo · 2014 · 85 citations · Cited by this paper
  18. 152P Efficacy and safety of relacorilant + nab-paclitaxel in patients aged ≥65 years with platinum-resistant ovarian cancer (PROC) in the phase III ROSELLA study (GOG-3073, ENGOT-ov72, APGOT-Ov10) · 2026 · Related
  19. Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma · Nadine H. Abdallah · 2020 · 57 citations · Cited by this paper
  20. 232eP GLP-1 receptor agonists and risk of incident endometrial, colorectal, and hepatocellular cancer: A systematic review and meta-analysis · 2026 · Related
  21. The combination of WGS and RNA-Seq is superior to conventional diagnostic tests in multiple myeloma: Ready for prime time? · Alexander Höllein · 2020 · 47 citations · Cited by this paper
  22. Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma · Niels Weinhold · 2015 · 44 citations · Cited by this paper
  23. Chromosome 8q24.1/c-MYCabnormality: a marker for high-risk myeloma · Isabella C. Glitza · 2014 · 41 citations · Cited by this paper
  24. The Prognostic Role of MYC Structural Variants Identified by NGS and FISH in Multiple Myeloma · Neeraj Sharma · 2021 · 38 citations · Cited by this paper
  25. Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma · James B. Smadbeck · 2019 · 37 citations · Cited by this paper
  26. High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease? · Priyanka Avinash Pophali · 2020 · 29 citations · Cited by this paper
  27. The impact of MYC gene amplification on the clinicopathological features and prognosis of radiation‐associated angiosarcomas of the breast · María Gabriela Kuba · 2021 · 28 citations · Cited by this paper
  28. Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma · Martin Kaiser · 2025 · 22 citations · Cited by this paper
  29. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT / UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial · Gordon C Cook · 2019 · 20 citations · Cited by this paper
  30. High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing · Anaïs Schavgoulidze · 2025 · 18 citations · Cited by this paper
  31. IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients · Xuehan Mao · 2020 · 11 citations · Cited by this paper
  32. Myc rearrangement redefines the stratification of high‐risk multiple myeloma · Xianghong Jin · 2024 · 6 citations · Cited by this paper

Source: OpenAlex (CC0)